Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

BIOLOGICAL: Pegylated Interferon Lambda (pegIFNλ)
DRUG: BMS-790052 (NS5A Inhibitor)
DRUG: Ribavirin (RBV)
DRUG: BMS-650032 (NS3 Protease Inhibitor)
BIOLOGICAL: Pegylated Interferon Alfa-2a (pegIFNα-2a)
BIOLOGICAL: Pegylated Interferon Lambda (pegIFNλ)
DRUG: Ribavirin (RBV)
BIOLOGICAL: Pegylated Interferon Lambda (pegIFNλ)
DRUG: Ribavirin (RBV)
DRUG: BMS-790052 (NS5A Inhibitor)
DRUG: BMS-650032 (NS3 Protease Inhibitor)
DRUG: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)
DRUG: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)
DRUG: Placebo for Ribavirin (RBV)
DRUG: Placebo for Ribavirin (RBV)

Sponsor

Bristol-Myers Squibb